


9/01/04

IFW

<b>TRANSMITTAL FORM</b> AUG 3 1 2004 (To be used for all correspondence after initial filing) PATENT & TRADEMARK OFFICE	Application Number	10/691,462
	Filing Date	October 21, 2003
	First Named Inventor	Orest W. Blaschuk
	Art Unit	1653
	Examiner Name	
	Attorney Docket No.	100086.410C2

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> CD(s), Number of CD(s) _____
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Request for Corrected Filing Receipt	<input type="checkbox"/> After Allowance Communication to Technology Center (TC)
<input type="checkbox"/> Amendment/Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Declaration	<input checked="" type="checkbox"/> Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449	<input type="checkbox"/> Statement under 37 CFR 3.73(b)	<input type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Cited References	<input type="checkbox"/> Terminal Disclaimer	_____
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	_____
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53		_____
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		_____

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Individual Name	Jeffrey E. Hundley, Ph.D., Patent Agent Reg. No. 42,676	Customer Number <b>00500</b>
Signature		
Date	August 31, 2004	

CERTIFICATE OF TRANSMISSION/MAILING
VIA EXPRESS MAIL

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

511498



EXPRESS MAIL NO. EV449562492US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Orest W. Blaschuk et al.  
Application No. : 10/691,462  
Filed : October 21, 2003  
For : COMPOUNDS AND METHODS FOR STIMULATING  $\beta$ -  
CATENIN MEDIATED GENE EXPRESSION AND  
DIFFERENTIATION

Art Unit : 1653  
Docket No. : 100086.410C2  
Date : August 31, 2004

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449. This application is a continuation and relies, under 35 U.S.C. § 120, on the earlier filing date of prior application USAN 09/545,433, filed April 5, 2000; which is a continuation-in-part of USAN 09/288,373, filed April 5, 1999, now abandoned. The references listed on the attached forms PTO-1449 were submitted to and/or cited by the Office in these prior applications and, therefore, are not required to be provided in the present application. If the Examiner wishes copies of reference will provided upon request.


As to any reference previously supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jeffrey E. Hundley, Ph.D., Patent Agent  
Registration No. 42,676

JEH:ljt

Enclosures:

Postcard  
Transmittal Form  
Forms PTO-1449 (2 Sheets)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

1511499

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

100086.410C2

APPLICATION NO.

10/691,462

## INFORMATION DISCLOSURE STATEMENT

(Indicate sheets if necessary)

APPLICANTS

Orest W. Blaschuk et al.

FILING DATE

October 21, 2003

GROUP ART UNIT

1653

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,631,237	05/20/97	Dzau et al.	514	44	
	AB	5,652,122	07/29/97	Frankel et al.	435	69.7	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AI	WO 98/42296	10/01/98	WIPO		
	AJ	WO 98/45319	10/15/98	WIPO		
	AK	WO 99/00138	01/07/99	WIPO		
	AL	WO 99/42481	08/26/99	WIPO		
	AM					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AN	Aberle et al., "β-catenin is a target for the ubiquitin-proteasome pathway," <i>The EMBO Journal</i> 16(13):3797-3804, 1997.
	AO	Bidault, Y. "The next generation of bioinformatics software: Examining proteins on the desktop computer", American Biotechnology Laboratory, p. 12, Jan. 2002.
	AP	Easwaran et al., "The Ubiquitin/Proteasome Pathway And Apc Regulation of Beta-Catenin/Lef Signaling," <i>Mol. Biol. Cell</i> 9:248a, Abstract No. 1440, 1998.
	AQ	Gat et al., "De Novo Hair Follicle Morphogenesis and Hair Tumors in Mice Expressing a Truncated β-Catenin in Skin," <i>Cell</i> 95:605-614, 1998

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
100086.410C2APPLICATION NO.  
10/691,462**INFORMATION DISCLOSURE STATEMENT**  
(Use several sheets if necessary)

## APPLICANTS

Orest W. Blaschuk et al.

## FILING DATE

October 21, 2003

## GROUP ART UNIT

1653

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BB					

**OTHER PRIOR ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

	BC	Hall et al., "Inhibition of FGF-stimulated phosphatidylinositol hydrolysis and neurite outgrowth by a cell-membrane permeable phosphopeptide," <i>Current Biology</i> 6(5):580-587, 1996.
	BD	Huber et al., "Nuclear localization of b-catenin by interaction with transcription factor LEF-1," <i>Mechanisms of Development</i> 59:3-10, 1996.
	BE	Longer, Mark A., "Sustained-Release Drug Delivery Systems," Remington's Pharmaceutical Sciences, 18 <sup>sup</sup> .th Ed., Chapter 91, pp. 1676-1693, 1990.
	BF	Mims et al., "A Nonexchangeable Apolipoprotein E Peptide That Mediates Binding to the Low Density Lipoprotein Receptor," <i>The Journal of Biological Chemistry</i> 269(32):20539-20547, 1994.
	BG	Oro and Scott, "Splitting Hairs: Dissecting Roles of Signaling Systems in Epidermal Development," <i>Cell</i> 95:575-578, 1998.
	BH	Orford et al., "Serine Phosphorylation-regulated Ubiquitination and Degradation of $\beta$ -Catenin," <i>The Journal of Biological Chemistry</i> 272(40):24735-24738, 1997.
	BI	Remington, J. P. Remington's Pharmaceutical Sciences. PA, Mack Publ. Co., 1990, p. 1692.
	BJ	Salomon et al., "Regulation of $\beta$ -Catenin Levels and Localization by Overexpression of Plakoglobin and Inhibition of the Ubiquitin-Proteasome System," <i>The Journal of Cell Biology</i> 139(5):1325-1335, 1997.
	BK	Willert and Nusse, " $\beta$ -catenin: a key mediator of Wnt signaling," <i>Current Opinion in Genetics and Development</i> 8:95-102, 1998.
	BL	Zhang et al., "Destabilization of $\beta$ -catenin by mutations in presenilin-1 potentiates neuronal apoptosis," <i>Nature</i> 395:698-702, 1998.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).